{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:27:28Z","timestamp":1793665648370,"version":"4.5.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41582-024-01053-8","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T11:40:35Z","timestamp":1736509235000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1792-8887","authenticated-orcid":false,"given":"Steven M.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-1175","authenticated-orcid":false,"given":"Francesco","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-8643","authenticated-orcid":false,"given":"Susanne J.","family":"van Veluw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1053_CR1","doi-asserted-by":"crossref","unstructured":"The Lancet. Lecanemab for Alzheimer\u2019s disease: tempering hype and hope. Lancet 400, 1899 (2022).","DOI":"10.1016\/S0140-6736(22)02480-1"},{"key":"1053_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46\u201354 (2003).","journal-title":"Neurology"},{"key":"1053_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367\u2013385 (2011).","journal-title":"Alzheimers Dement."},{"key":"1053_CR4","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","volume":"43","author":"PM Cogswell","year":"2022","unstructured":"Cogswell, P. M. et al. Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. Am. J. Neuroradiol. 43, E19\u2013E35 (2022).","journal-title":"Am. J. Neuroradiol."},{"key":"1053_CR5","first-page":"10","volume":"3","author":"R Vandenberghe","year":"2017","unstructured":"Vandenberghe, R. et al. Active Abeta immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study. Alzheimers Dement. 3, 10\u201322 (2017).","journal-title":"Alzheimers Dement."},{"key":"1053_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(09)70013-4","volume":"8","author":"SM Greenberg","year":"2009","unstructured":"Greenberg, S. M. et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 8, 165\u2013174 (2009).","journal-title":"Lancet Neurol."},{"key":"1053_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3174\/ajnr.A1355","volume":"30","author":"RN Nandigam","year":"2009","unstructured":"Nandigam, R. N. et al. MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. Am. J. Neuroradiol. 30, 338\u2013343 (2009).","journal-title":"Am. J. Neuroradiol."},{"key":"1053_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling, R. et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241\u2013249 (2012).","journal-title":"Lancet Neurol."},{"key":"1053_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway, S. et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79, 13\u201321 (2022).","journal-title":"JAMA Neurol."},{"key":"1053_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ana.23857","volume":"73","author":"F Piazza","year":"2013","unstructured":"Piazza, F. et al. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann. Neurol. 73, 449\u2013458 (2013).","journal-title":"Ann. Neurol."},{"key":"1053_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2015.4078","volume":"73","author":"E Auriel","year":"2016","unstructured":"Auriel, E. et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 73, 197\u2013202 (2016).","journal-title":"JAMA Neurol."},{"key":"1053_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou, A. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 21, 714\u2013725 (2022).","journal-title":"Lancet Neurol."},{"key":"1053_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin, N. et al. Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann. Neurol. 92, 729\u2013744 (2022).","journal-title":"Ann. Neurol."},{"key":"1053_CR14","doi-asserted-by":"publisher","first-page":"107436","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107436","volume":"32","author":"M Amin","year":"2023","unstructured":"Amin, M. et al. The prevalence of radiological cerebral amyloid angiopathy-related inflammation in patients with cerebral amyloid angiopathy. J. Stroke Cerebrovasc. Dis. 32, 107436 (2023).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"1053_CR15","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1212\/WNL.0000000000006780","volume":"92","author":"J Graff-Radford","year":"2019","unstructured":"Graff-Radford, J. et al. Cerebral microbleeds: prevalence and relationship to amyloid burden. Neurology 92, e253\u2013e262 (2019).","journal-title":"Neurology"},{"key":"1053_CR16","volume":"9","author":"LS Honig","year":"2023","unstructured":"Honig, L. S. et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease. Alzheimers Dement. 9, e12377 (2023).","journal-title":"Alzheimers Dement."},{"key":"1053_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1053_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish, N. J. et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N. Engl. J. Med. 388, 478\u2013479 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1053_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova, E. et al. Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat. Commun. 14, 8220 (2023).","journal-title":"Nat. Commun."},{"key":"1053_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig, L. S. et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 16, 105 (2024).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"1053_CR21","unstructured":"Eli Lilly and Company. Donanemab for the Treatment of Patients with Early Symptomatic Alzheimer\u2019s Disease: Sponsor Briefing Document. https:\/\/www.fda.gov\/media\/179167\/download (2024)."},{"key":"1053_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209582","volume":"103","author":"J Neves Briard","year":"2024","unstructured":"Neves Briard, J., Duquette, A., Cayrol, R. & Lapalme-Remis, S. Refractory status epilepticus in a patient with aducanumab-induced amyloid-related imaging abnormalities. Neurology 103, e209582 (2024).","journal-title":"Neurology"},{"key":"1053_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki, S. et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 79, 1113\u20131121 (2022).","journal-title":"JAMA Neurol."},{"key":"1053_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1096\u20131107 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1053_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61691-2","volume":"14","author":"L Soderberg","year":"2024","unstructured":"Soderberg, L. et al. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Sci. Rep. 14, 10868 (2024).","journal-title":"Sci. Rep."},{"key":"1053_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki, S. et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res. Ther. 9, 95 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"1053_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1053_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1053_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","volume":"85","author":"E Liu","year":"2015","unstructured":"Liu, E. et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85, 692\u2013700 (2015).","journal-title":"Neurology"},{"key":"1053_CR30","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway, S. et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061\u20132070 (2009).","journal-title":"Neurology"},{"key":"1053_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1053_CR32","unstructured":"Wang, H. et al. The effect of different donanemab dosing regimens on ARIA-E and amyloid lowering in adults with early symptomatic Alzheimer\u2019s disease: primary outcome results from TRAILBLAZER-ALZ 6, Eli Lilly and Company. https:\/\/assets.ctfassets.net\/mpejy6umgthp\/4vbew8MSRVpgzDkYrcQzSU\/45e7cd8dc17cb50b581582a5b2966f46\/DV-021572_24wTB6-MDD.pdf (2024)."},{"key":"1053_CR33","doi-asserted-by":"publisher","unstructured":"Greenberg, S. M. et al. ARIA insights from the donanemab trials. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000205071 (2024).","DOI":"10.1212\/WNL.0000000000205071"},{"key":"1053_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207919","volume":"102","author":"SJ Loomis","year":"2024","unstructured":"Loomis, S. J. et al. Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies. Neurology 102, e207919 (2024).","journal-title":"Neurology"},{"key":"1053_CR35","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamaneurol.2014.681","volume":"71","author":"JM Ringman","year":"2014","unstructured":"Ringman, J. M. et al. Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol. 71, 878\u2013883 (2014).","journal-title":"JAMA Neurol."},{"key":"1053_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.1782","volume":"77","author":"RW Regenhardt","year":"2020","unstructured":"Regenhardt, R. W. et al. Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 77, 1\u201310 (2020).","journal-title":"JAMA Neurol."},{"key":"1053_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41583-023-00776-9","volume":"25","author":"J Blumenfeld","year":"2024","unstructured":"Blumenfeld, J., Yip, O., Kim, M. J. & Huang, Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat. Rev. Neurosci. 25, 91\u2013110 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"1053_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/WAD.0b013e318256ecd8","volume":"27","author":"JL De Reuck","year":"2013","unstructured":"De Reuck, J. L. et al. Microbleeds in postmortem brains of patients with Alzheimer disease: a T2*-weighted gradient-echo 7.0 T magnetic resonance imaging study. Alzheimer Dis. Assoc. Disord. 27, 162\u2013167 (2013).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"1053_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290344","volume":"18","author":"D Montano","year":"2023","unstructured":"Montano, D. Public health impact of antihypertensive medication use on arterial blood pressure: a pooled cross-sectional analysis of population health surveys. PLoS ONE 18, e0290344 (2023).","journal-title":"PLoS ONE"},{"key":"1053_CR40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jama.2015.10082","volume":"314","author":"A Biffi","year":"2015","unstructured":"Biffi, A. et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 314, 904\u2013912 (2015).","journal-title":"JAMA"},{"key":"1053_CR41","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1212\/WNL.0000000000010017","volume":"95","author":"P Fotiadis","year":"2020","unstructured":"Fotiadis, P. et al. White matter atrophy in cerebral amyloid angiopathy. Neurology 95, e554\u2013e562 (2020).","journal-title":"Neurology"},{"key":"1053_CR42","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll, J. A. R. et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer\u2019s disease. Brain 142, 2113\u20132126 (2019).","journal-title":"Brain"},{"key":"1053_CR43","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-014-1340-9","volume":"128","author":"K Sakai","year":"2014","unstructured":"Sakai, K. et al. Abeta immunotherapy for Alzheimer\u2019s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol. 128, 777\u2013789 (2014).","journal-title":"Acta Neuropathol."},{"key":"1053_CR44","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche, D. et al. Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain 131, 3299\u20133310 (2008).","journal-title":"Brain"},{"key":"1053_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll, J. A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448\u2013452 (2003).","journal-title":"Nat. Med."},{"key":"1053_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer, I., Boada Rovira, M., Sanchez Guerra, M. L., Rey, M. J. & Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer\u2019s disease. Brain Pathol. 14, 11\u201320 (2004).","journal-title":"Brain Pathol."},{"key":"1053_CR47","doi-asserted-by":"publisher","first-page":"fcac021","DOI":"10.1093\/braincomms\/fcac021","volume":"4","author":"AA Scherlek","year":"2022","unstructured":"Scherlek, A. A. et al. Histopathological correlates of haemorrhagic lesions on ex vivo magnetic resonance imaging in immunized Alzheimer\u2019s disease cases. Brain Commun. 4, fcac021 (2022).","journal-title":"Brain Commun."},{"key":"1053_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059735","volume":"8","author":"AE Roher","year":"2013","unstructured":"Roher, A. E. et al. Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS ONE 8, e59735 (2013).","journal-title":"PLoS ONE"},{"key":"1053_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey, E. D. et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 144, 143\u2013153 (2022).","journal-title":"Acta Neuropathol."},{"key":"1053_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani, R. J. et al. Neuropathology of anti-amyloid-beta immunotherapy: a case report. J. Alzheimers Dis. 93, 803\u2013813 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00018-024-05277-1","volume":"81","author":"SJ van Veluw","year":"2024","unstructured":"van Veluw, S. J. et al. Is CAA a perivascular brain clearance disease? A discussion of the evidence to date and outlook for future studies. Cell. Mol. Life Sci. 81, 239 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"1053_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","volume":"120","author":"D Boche","year":"2010","unstructured":"Boche, D., Denham, N., Holmes, C. & Nicoll, J. A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer\u2019s disease pathogenesis. Acta Neuropathol. 120, 369\u2013384 (2010).","journal-title":"Acta Neuropathol."},{"key":"1053_CR53","doi-asserted-by":"publisher","first-page":"fcac245","DOI":"10.1093\/braincomms\/fcac245","volume":"4","author":"MG Kozberg","year":"2022","unstructured":"Kozberg, M. G. et al. Blood\u2013brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy. Brain Commun. 4, fcac245 (2022).","journal-title":"Brain Commun."},{"key":"1053_CR54","doi-asserted-by":"publisher","first-page":"e1809","DOI":"10.1212\/WNL.0000000000012778","volume":"97","author":"L Antolini","year":"2021","unstructured":"Antolini, L. et al. Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation: a multicenter prospective longitudinal cohort study. Neurology 97, e1809\u2013e1822 (2021).","journal-title":"Neurology"},{"key":"1053_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3233\/JAD-180269","volume":"64","author":"D Renard","year":"2018","unstructured":"Renard, D. et al. Cerebral amyloid angiopathy and cerebral amyloid angiopathy-related inflammation: comparison of hemorrhagic and DWI MRI features. J. Alzheimers Dis. 64, 1113\u20131121 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR56","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209548","volume":"103","author":"L Grangeon","year":"2024","unstructured":"Grangeon, L. et al. Cerebral amyloid angiopathy-related inflammation and biopsy-positive primary angiitis of the CNS: a comparative study. Neurology 103, e209548 (2024).","journal-title":"Neurology"},{"key":"1053_CR57","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ana.10810","volume":"55","author":"JA Eng","year":"2004","unstructured":"Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W. & Greenberg, S. M. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann. Neurol. 55, 250\u2013256 (2004).","journal-title":"Ann. Neurol."},{"key":"1053_CR58","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1440-1789.2011.01283.x","volume":"32","author":"K Sakai","year":"2012","unstructured":"Sakai, K., Hayashi, S., Sanpei, K., Yamada, M. & Takahashi, H. Multiple cerebral infarcts with a few vasculitic lesions in the chronic stage of cerebral amyloid angiopathy-related inflammation. Neuropathology 32, 551\u2013556 (2012).","journal-title":"Neuropathology"},{"key":"1053_CR59","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JAD-150621","volume":"50","author":"D Renard","year":"2016","unstructured":"Renard, D. et al. Cerebrospinal fluid Alzheimer\u2019s disease biomarkers in cerebral amyloid angiopathy-related inflammation. J. Alzheimers Dis. 50, 759\u2013764 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR60","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3233\/JAD-220838","volume":"91","author":"K Sakai","year":"2023","unstructured":"Sakai, K. et al. Cerebrospinal fluid biomarkers and amyloid-beta elimination from the brain in cerebral amyloid angiopathy-related inflammation. J. Alzheimers Dis. 91, 1173\u20131183 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-150614","volume":"50","author":"M Carmona-Iragui","year":"2016","unstructured":"Carmona-Iragui, M. et al. Cerebrospinal fluid anti-amyloid-beta autoantibodies and amyloid PET in cerebral amyloid angiopathy-related inflammation. J. Alzheimers Dis. 50, 1\u20137 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR62","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2169\/internalmedicine.53.1731","volume":"53","author":"R Sengoku","year":"2014","unstructured":"Sengoku, R. et al. (11)C-PiB PET imaging of encephalopathy associated with cerebral amyloid angiopathy. Intern. Med. 53, 1997\u20132000 (2014).","journal-title":"Intern. Med."},{"key":"1053_CR63","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3233\/JAD-170843","volume":"61","author":"D Renard","year":"2018","unstructured":"Renard, D. et al. Cerebrospinal fluid, MRI, and florbetaben-PET in cerebral amyloid angiopathy-related inflammation. J. Alzheimers Dis. 61, 1107\u20131117 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR64","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3233\/JAD-150070","volume":"46","author":"JC DiFrancesco","year":"2015","unstructured":"DiFrancesco, J. C. et al. Recurrence of cerebral amyloid angiopathy-related inflammation: a report of two cases from the iCAbeta International network. J. Alzheimers Dis. 46, 1071\u20131077 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"1053_CR65","doi-asserted-by":"publisher","first-page":"1153305","DOI":"10.3389\/fneur.2023.1153305","volume":"14","author":"JY Yang","year":"2023","unstructured":"Yang, J. Y., Chu, Y. T., Tsai, H. H. & Jeng, J. S. Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review. Front. Neurol. 14, 1153305 (2023).","journal-title":"Front. Neurol."},{"key":"1053_CR66","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/ane.13382","volume":"143","author":"K Sakai","year":"2021","unstructured":"Sakai, K. et al. Cerebrospinal fluid cytokines and metalloproteinases in cerebral amyloid angiopathy-related inflammation. Acta Neurol. Scand. 143, 450\u2013457 (2021).","journal-title":"Acta Neurol. Scand."},{"key":"1053_CR67","doi-asserted-by":"publisher","first-page":"e1265","DOI":"10.1212\/WNL.0000000000200892","volume":"99","author":"F Piazza","year":"2022","unstructured":"Piazza, F. et al. Association of microglial activation with spontaneous ARIA-E and CSF levels of anti-abeta autoantibodies. Neurology 99, e1265\u2013e1277 (2022).","journal-title":"Neurology"},{"key":"1053_CR68","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11910-022-01235-1","volume":"22","author":"KE Foley","year":"2022","unstructured":"Foley, K. E. & Wilcock, D. M. Vascular considerations for amyloid immunotherapy. Curr. Neurol. Neurosci. Rep. 22, 709\u2013719 (2022).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1053_CR69","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer, M. et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298, 1379 (2002).","journal-title":"Science"},{"key":"1053_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock, D. M. et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1, 24 (2004).","journal-title":"J. Neuroinflammation"},{"key":"1053_CR71","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke, M. M. et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25, 629\u2013636 (2005).","journal-title":"J. Neurosci."},{"key":"1053_CR72","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","volume":"9","author":"W Zago","year":"2013","unstructured":"Zago, W. et al. Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9, S105\u2013S115 (2013).","journal-title":"Alzheimers Dement."},{"key":"1053_CR73","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","volume":"28","author":"S Schroeter","year":"2008","unstructured":"Schroeter, S. et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28, 6787\u20136793 (2008).","journal-title":"J. Neurosci."},{"key":"1053_CR74","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos, R. B. et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76, 908\u2013920 (2012).","journal-title":"Neuron"},{"key":"1053_CR75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor, X. et al. Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice. Mol. Neurodegener. 18, 59 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1053_CR76","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor, X. et al. Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 19, 77 (2024).","journal-title":"Mol. Neurodegener."},{"key":"1053_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-115","volume":"8","author":"DM Wilcock","year":"2011","unstructured":"Wilcock, D. M. et al. Activation of matrix metalloproteinases following anti-Abeta immunotherapy; implications for microhemorrhage occurrence. J. Neuroinflammation 8, 115 (2011).","journal-title":"J. Neuroinflammation"},{"key":"1053_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13195-018-0447-y","volume":"10","author":"L Pradier","year":"2018","unstructured":"Pradier, L. et al. SAR228810: an antibody for protofibrillar amyloid beta peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). Alzheimers Res. Ther. 10, 117 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"1053_CR79","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/ijms25020817","volume":"25","author":"AF Batista","year":"2024","unstructured":"Batista, A. F., Khan, K. A., Papavergi, M. T. & Lemere, C. A. The importance of complement-mediated immune signaling in Alzheimer\u2019s disease pathogenesis. Int. J. Mol. Sci. 25, 817 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1053_CR80","unstructured":"Romano, G. et al. INVOKE-2: An Update on the Phase2 Trial of AL002 in Early AD. https:\/\/investors.alector.com\/static-files\/7876dcd7-f1ed-4928-a579-d2906482f941 (2023)."},{"key":"1053_CR81","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","volume":"23","author":"CRS Belder","year":"2024","unstructured":"Belder, C. R. S. et al. Brain volume change following anti-amyloid beta immunotherapy for Alzheimer\u2019s disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol. 23, 1025\u20131034 (2024).","journal-title":"Lancet Neurol."},{"key":"1053_CR82","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves, F., Kalinowski, P. & Ayton, S. Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and meta-analysis. Neurology 100, e2114\u2013e2124 (2023).","journal-title":"Neurology"},{"key":"1053_CR83","unstructured":"US Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Aducanumab. Reference ID761178. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761178s011lbl.pdf (2023)."},{"key":"1053_CR84","unstructured":"US Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Lecanemab. Reference id761269. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s000lbl.pdf (2023)."},{"key":"1053_CR85","unstructured":"US Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Donanemab. Reference id761248. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf (2024)."},{"key":"1053_CR86","unstructured":"European Medicines Agency. Leqembi. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi (2024)."},{"key":"1053_CR87","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings, J. et al. Aducanumab: appropriate use recommendations. J. Prev. Alzheimers Dis. 8, 398\u2013410 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1053_CR88","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 10, 362\u2013377 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1053_CR89","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings, J. et al. Aducanumab: appropriate use recommendations update. J. Prev. Alzheimers Dis. 9, 221\u2013230 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1053_CR90","unstructured":"UK Medicines and Healthcare Products Regulatory Agency. Public Assessment Report National Procedure: Leqembi. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/6ed2db79b7202feb5a8edbecfa5c35bb434381e6 (2024)."},{"key":"1053_CR91","first-page":"e426","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton, P. K. et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 138, e426\u2013e483 (2018).","journal-title":"Circulation"},{"key":"1053_CR92","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 41, 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"key":"1053_CR93","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00415-024-12205-7","volume":"271","author":"R Agbonon","year":"2024","unstructured":"Agbonon, R. et al. Cerebral microbleeds and risk of symptomatic hemorrhagic transformation following mechanical thrombectomy for large vessel ischemic stroke. J. Neurol. 271, 2631\u20132638 (2024).","journal-title":"J. Neurol."},{"key":"1053_CR94","doi-asserted-by":"publisher","first-page":"eabd7522","DOI":"10.1126\/scitranslmed.abd7522","volume":"13","author":"M Xiong","year":"2021","unstructured":"Xiong, M. et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1053_CR95","doi-asserted-by":"publisher","unstructured":"Pizzo, M. E. et al. Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.07.26.604664 (2024).","DOI":"10.1101\/2024.07.26.604664"},{"key":"1053_CR96","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm, H. P. et al. Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs 15, 2261509 (2023).","journal-title":"MAbs"},{"key":"1053_CR97","unstructured":"Kulic, L. et al. Latest interim results from the Brainshuttle AD Study, a phase IB\/IIA study of trontinemab in people with Alzheimer\u2019s Disease. Roche https:\/\/medically.roche.com\/global\/en\/neuroscience\/ctad-2024\/medical-material\/CTAD-2024-presentation-kulic-latest-interim-results-from-brainshuttle-ad-study-pdf.html (2024)."},{"key":"1053_CR98","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe, S. L. et al. Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s Disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J. Prev. Alzheimer\u2019s Dis. 8, 414\u2013424\u00a0(2021).","journal-title":"J. Prev. Alzheimer\u2019s Dis."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01053-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:36:51Z","timestamp":1743773811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01053-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1053"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-01053-8","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"19 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M.G. has served as consultant for Eli Lilly and Company and serves on data monitoring committees for Alzheimer Disease clinical trials for Bristol Meyers Squibb and Washington University. S.J.v.V. has served as consultant for Biogen and Eisai and receives industry support from Sanofi (iAward) and Therini Bio (sponsored research agreement).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}